• Shopping cart is empty.

    The International Society for Aerosols in Medicine

    Fakhrul Ahsan

    Fakhrul Ahsan

    Fakhrul Ahsan

    Texas Tech University Health Sciences Center School of Pharmacy  
    Amarillo, Texas
    USA

    Dr. Fakhrul Ahsan is a University Distinguished Professor in the Department of Pharmaceutical Sciences and Head of the Graduate Program in Pharmaceutical Sciences at the Texas Tech University Health Sciences Center (TTUHSC) School of Pharmacy in Amarillo, Texas. A pharmacist by training, Dr. Ahsan earned his pharmacy degree from the University of Dhaka in Bangladesh and Ph.D. in Pharmaceutics from Complutense University of Madrid. He received his postdoctoral training from the University of Alabama at Birmingham. Dr. Ahsan’s research revolves around the development of novel formulations for the pulmonary delivery of small- and large-molecular-weight therapeutic agents for the treatment of respiratory disorders, including asthma and pulmonary hypertension. Recently, he has diversified his research toward tissue chips for PAH, bioprinting and lung-tissue engineering. He is a member of the Editorial Boards of the European Journal of Pharmaceutical Sciences and the Journal of Pharmacy and Pharmaceutical Sciences, and was an Associate Editor of the Journal of Drug Targeting. He also serves in various NIH and DoD study sections.

    Microfluidic devices for studying pulmonary vascular diseases

    Abstract 

    Pulmonary arterial hypertension (PAH) encompasses a group of disorders. Many facets concerning the development and progression of PAH remain unclear. PAH investigators use intact animal or cellular models that are not malleable enough to accommodate investigation of the overlapping cellular and molecular processes involved in the development of this disease. In this project, we developed a device, called PAH-on-a-chip (Fig. 1), wherein we grew cells from arteries of PAH patients, the latter giving rise to various cellular phenomena resembling PAH pathophysiology. This miniaturized device will contribute enormously to our understanding of this under-investigated disorder and expediting drug development for PAH. This device can be used to assess the pathophysiology of various cardiopulmonary disease, develop sex and age-based therapy for PAH and other pulmonary vascular diseases.